A single but durable stable disease sends the microcap's stock up 730%.
ApexOnco Front Page
Recent articles
Data on J&J’s Tecvayli and Pfizer’s Elrexfio in relapsed multiple myeloma are due soon.
More bad news for CD47 as response rates in Aspen-06 wane, and the company turns to a subgroup.
The companies hope to be as efficacious as ex vivo therapy, with convenience and safety advantages.
The company stops dosing in the troubled Tamarack trial, and is going quiet until ESMO.
But the company hasn’t given details, and used a historical control rather than the study’s own control arm.
Meanwhile, the RayzeBio-originated RYZ101 is back in Action.
Now in Bristol’s hands, BMS-986442 is set to deliver its first clinical data.